Document Detail

Ribonucleases and immunoRNases as anticancer drugs.
MedLine Citation:
PMID:  19689337     Owner:  NLM     Status:  MEDLINE    
Ribonucleases degrade RNA, now considered an important drug target. The parent member of this protein superfamily is bovine pancreatic RNase A that functions as a digestive enzyme. Other physiological roles and activities have been ascribed to more recently discovered members of this superfamily. Angiogenin was isolated by following angiogenic activity from cell culture media conditioned by colon cancer cells. ONCONASE kills tumor cells in vitro and in vivo and has advanced to a phase IIIb confirmatory clinical trial for the treatment of unresectable malignant mesothelioma. All three of these RNA degrading enzymes have been used to generate immunoRNases; chemical conjugates and ligand-RNase fusion proteins, for cancer therapy. The properties of each of these RNases are described along with the increasingly sophisticated construction of recombinant immunoRNases. The advantages of using RNase as an antibody payload is compared to using plant or bacterial toxins in the construction of immunotoxins, a related strategy for specifically killing malignant cells.
S M Rybak; M A E Arndt; T Schirrmann; S Dübel; J Krauss
Related Documents :
21171517 - Atypical dermatofibroma with predominant epithelioid/deciduoid-like cell component. his...
19608627 - The microrna mir-92 increases proliferation of myeloid cells and by targeting p63 modul...
21104057 - Cell-based microarrays of infectious adenovirus encoding short hairpin rna (shrna).
2439387 - Lack of synthesis of pentamer igm in xenopus oocytes after injection of poly(a)+ rna fr...
15212167 - Transfection efficiency and cytotoxicity of nonviral gene transfer reagents in human sm...
3367927 - Development of a rodent lung macrophage chromosome aberration assay.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current pharmaceutical design     Volume:  15     ISSN:  1873-4286     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2009  
Date Detail:
Created Date:  2009-08-19     Completed Date:  2009-12-21     Revised Date:  2011-07-19    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  2665-75     Citation Subset:  IM    
Bionanomics, LLC, 411 Walnut Street, Green Cove Springs, FL 32043, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Drug Discovery / methods*
Immunotoxins / therapeutic use
Models, Molecular
Recombinant Proteins / biosynthesis,  therapeutic use
Ribonuclease, Pancreatic / therapeutic use
Ribonucleases / immunology,  physiology,  therapeutic use*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Immunotoxins; 0/Recombinant Proteins; EC 3.1.-/Ribonucleases; EC 3.1.-/ranpirnase; EC 3.1.27.-/angiogenin; EC, Pancreatic; EC RNase 2, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Next Document:  Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms an...